RECRUITING

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder

Talk to us

Conditions

Generalized Anxiety Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

Official Title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama

Quick Facts

Study Start:2025-01-29
Study Completion:2027-05-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06809595

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 74 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female: must be between 18 (or the legal age of consent in the jurisdiction in which the study is taking place) and 74 years of age inclusive, at the time of signing the informed consent.
  2. 2. Diagnosis of GAD per DSM-5
  3. 3. HAM-A Total Score ≥20
  1. 1. Any psychiatric disorder (other than generalized anxiety disorder)
  2. 2. First degree relative with or lifetime history of a psychotic disorder.
  3. 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine).
  4. 4. Any clinically significant unstable illness.

Contacts and Locations

Study Contact

Mind Medicine, Inc. Clinical Trials Info Requests
CONTACT
1-332-282-0479
ClinicalTrials@Mindmed.co

Study Locations (Sites)

Preferred Research Partners, Inc.
Little Rock, Arkansas, 72211
United States
West Los Angeles VA Medical Center
Los Angeles, California, 90073
United States
Cenexel-CNS
Torrance, California, 90504
United States
Bradenton Research Center, Inc.
Bradenton, Florida, 34205
United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, 32801
United States
Atlanta Center for Medical Research
Atlanta, Georgia, 30331
United States
Sheppard Pratt Health System
Towson, Maryland, 21204
United States
Copley Clinical
Boston, Massachusetts, 02116
United States
Princeton Medical Institute
Princeton, New Jersey, 08540
United States
University of Cincinnati Psychiatry- Anxiety Disorders Research Program
Cincinnati, Ohio, 45219
United States
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, 44720
United States
Austin Clinical Trial Partners
Austin, Texas, 78737
United States
Cedar Clinical Research
Murray, Utah, 84107
United States
Core Clinical Research
Everett, Washington, 98201
United States

Collaborators and Investigators

Sponsor: Mind Medicine, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-29
Study Completion Date2027-05-04

Study Record Updates

Study Start Date2025-01-29
Study Completion Date2027-05-04

Terms related to this study

Additional Relevant MeSH Terms

  • Generalized Anxiety Disorder